CCKBR
MOLECULAR TARGETcholecystokinin B receptor
CCKBR (cholecystokinin B receptor) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CCKBR
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | damgo | 5.09 | 161 |
| 2 | l 365260 | 3.50 | 32 |
| 3 | devazepide | 3.26 | 25 |
| 4 | Tetragastrin L-Tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide. | 2.30 | 9 |
| 5 | ci 988 | 2.08 | 7 |
| 6 | netazepide | 1.79 | 5 |
| 7 | Fluoxetine | 0.69 | 1 |
| 8 | Cholecystokinin | 0.69 | 1 |
| 9 | Fidaxomicin | 0.69 | 1 |
| 10 | Ondansetron | 0.69 | 1 |
About CCKBR as a Drug Target
CCKBR (cholecystokinin B receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented CCKBR interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CCKBR inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.